Feed ABSI
AB

Absci Corporation ABSI · NASDAQ

$8.54 +3.52% (+$0.29)

Market cap
$1.47B
Enterprise value
$1.36B
P/E
-
Forward P/E
-
PEG
-
P/S
938.9x
P/FCF
-
EV/EBITDA
-
ROIC
-52.2%
Gross margin
-255.9%
Net margin
-7,756.4%
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
-
Beta
2.28
Free float
86.3%

About the company

Absci Corporation (ABSI) is an innovative biotechnology company headquartered in the USA, specializing in rapid protein development and production for the pharmaceutical and biotechnology industries. The company harnesses advanced artificial intelligence and automation technologies to expedite the protein design and engineering process, enabling swift response to market needs and drug development. Absci Corporation has emerged as a crucial partner for pharmaceutical firms seeking innovative and efficient approaches to drug development and therapies. Investors keen on advanced biotechnology and innovations in the pharmaceutical sector may recognize the potential for long-term growth and contributions to the healthcare industry in Absci Corporation (ABSI) shares.

Sector

Healthcare

Industry

Biotechnology

CEO

Sean McClain

Employees

140

Headquarters

Vancouver

Valuation

Is today's price reasonable?

Growth and estimates

Is it growing, and what comes next?

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

Financial health

Can it carry its debt?

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.